{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:29:01Z","timestamp":1773368941701,"version":"3.50.1"},"reference-count":54,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Plasma\u2010derived medicinal products (PDMPs) are life\u2010saving and life\u2010improving therapies, but the raw material is in short supply: Europe depends on importation from countries including the United States. Plasma from donors resident in the United Kingdom has not been fractionated since 1999 when a precautionary measure was introduced in response to the outbreak of variant Creutzfeldt\u2013Jakob disease (vCJD). Cases of vCJD have been far fewer than originally predicted in the 1990s. Since the introduction of leucodepletion in 1999, and accounting for the incubation period, more than 40 million UK\u2010derived blood components have been issued with no reports of TT vCJD. In February 2021, the UK Government authorized manufacture of immunoglobulin from UK plasma. Following separate reviews concluding no significant difference in the risk posed, the United States, Australia, Ireland and Hong Kong also lifted their deferrals of blood donors with a history of living in the United Kingdom. Other countries are actively reviewing their position. Demand is rising for PDMPs, and Europe faces a threat of supply shortages. Industry and patient groups are clear that using UK plasma would bring significant immediate benefits to patients and to the resilience of the European supply chain. From this scientific review, we conclude that UK plasma is safe for fractionation and urge blood regulators and operators to take account of this safety profile when considering fractionation of UK plasma, and to revise their guidelines on the deferral of donors who have lived in, or received a transfusion in, the United Kingdom.<\/jats:p>","DOI":"10.1111\/vox.13416","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T19:34:56Z","timestamp":1678217696000},"page":"345-353","source":"Crossref","is-referenced-by-count":7,"title":["Safety profile of plasma for fractionation donated in the United Kingdom, with respect to variant<scp>Creutzfeldt\u2013Jakob<\/scp>disease"],"prefix":"10.1111","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7761-7138","authenticated-orcid":false,"given":"Stephen","family":"Thomas","sequence":"first","affiliation":[{"name":"Joint UK Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barnaby","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Health and Social Care London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9696-8953","authenticated-orcid":false,"given":"Dragoslav","family":"Domanovi\u0107","sequence":"additional","affiliation":[{"name":"European Blood Alliance Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7135-6691","authenticated-orcid":false,"given":"Koen","family":"Kramer","sequence":"additional","affiliation":[{"name":"Communication, Philosophy, Technology, and Education section Wageningen University Wageningen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Klochkov","sequence":"additional","affiliation":[{"name":"CSL Behring Bern Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujan","family":"Sivasubramaniyam","sequence":"additional","affiliation":[{"name":"CSL Behring Haywards Heath UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Miloslavich","sequence":"additional","affiliation":[{"name":"Marketing Research Bureau Greenacres USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Philippe","family":"Plan\u00e7on","sequence":"additional","affiliation":[{"name":"Epodin La Baule France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Rossi","sequence":"additional","affiliation":[{"name":"International Plasma and Fractionation Association Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominika","family":"Misztela","sequence":"additional","affiliation":[{"name":"Plasma Protein Therapeutics Association Annapolis Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Kirkpatrick","sequence":"additional","affiliation":[{"name":"Northern Ireland Blood Transfusion Service Belfast UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail","family":"Miflin","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Birchall","sequence":"additional","affiliation":[{"name":"Welsh Blood Service Cardiff UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorna","family":"McLintock","sequence":"additional","affiliation":[{"name":"Scottish National Blood Transfusion Service Edinburgh UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Knight","sequence":"additional","affiliation":[{"name":"UK National CJD Research &amp; Surveillance Unit University of Edinburgh Edinburgh UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000696"},{"key":"e_1_2_14_3_1","unstructured":"Medicines and Healthcare products Regulatory Agency.Critical risk assessment report: use of UK plasma for the manufacture of immunoglobulins and vCJD risk. GOV.UK. [cited 2022 Oct 28]. Available from:https:\/\/www.gov.uk\/government\/publications\/critical\u2010risk\u2010assessment\u2010report\u2010use\u2010of\u2010uk\u2010plasma\u2010for\u2010the\u2010manufacture\u2010of\u2010immunoglobulins\u2010and\u2010vcjd\u2010risk\/critical\u2010risk\u2010assessment\u2010report\u2010use\u2010of\u2010uk\u2010plasma\u2010for\u2010the\u2010manufacture\u2010of\u2010immunoglobulins\u2010and\u2010vcjd\u2010risk"},{"key":"e_1_2_14_4_1","unstructured":"Therapeutic Goods Administration (TGA).TGA approval to change blood donation rules relating to vCJD deferral. Therapeutic goods administration (TGA). 2022 [cited 2023 Jan 6]. Available from:https:\/\/www.tga.gov.au\/news\/news\/tga\u2010approval\u2010change\u2010blood\u2010donation\u2010rules\u2010relating\u2010vcjd\u2010deferral"},{"key":"e_1_2_14_5_1","unstructured":"Food and Drug Administration.Recommendations to reduce the possible risk of transmission of Creutzfeldt\u2010Jakob disease and variant Creutzfeldt\u2010Jakob disease by blood and blood components; Guidance for Industry. [cited 2022 Oct 28]. Available from:https:\/\/www.fda.gov\/media\/124156\/download"},{"key":"e_1_2_14_6_1","unstructured":"Irish Blood Transfusion Service.vCJD. [cited 2022 Oct 31]. Available from:https:\/\/www.giveblood.ie\/can-i-give-blood\/keeping-blood-safe\/vcjd\/"},{"key":"e_1_2_14_7_1","doi-asserted-by":"crossref","unstructured":"Hong Kong Red Cross Blood Transfusion Service.Recent Changes to Donation Criteria (Updated: 21 Dec 2022). [cited 2023 Jan 6]. Available from:https:\/\/www5.ha.org.hk\/rcbts\/news\/news20190310?lang=en","DOI":"10.3126\/jngmc.v21i2.62714"},{"key":"e_1_2_14_8_1","unstructured":"UK Blood Services Forum.UK plasma for fractionation. Review of Safety Profile 2022. Available from:https:\/\/www.transfusionguidelines.org\/document\u2010library\/documents\/position\u2010paper\u2010on\u2010uk\u2010plasma\u2010uk\u2010forum\u20102022\/download\u2010file\/Position%20paper%20on%20UK%20plasma%20\u2010%20UK%20Forum%202022.pdf"},{"key":"e_1_2_14_9_1","unstructured":"Committee on the Safety of Medicines.Summary of Meeting 1998. [cited 2022 Nov 28]. Available from:https:\/\/webarchive.nationalarchives.gov.uk\/ukgwa\/20140205132315mp_\/http:\/www.mhra.gov.uk\/home\/groups\/l\u2010cs\u2010el\/documents\/committeedocument\/con003339.pdf"},{"key":"e_1_2_14_10_1","unstructured":"Proposal for a Regulation on substances of human origin. [cited 2022 Oct 31]. Available from:https:\/\/health.ec.europa.eu\/blood-tissues-cells-and-organs\/overview\/proposal-regulation-substances-human-origin_en"},{"key":"e_1_2_14_11_1","unstructured":"European Medicines Agency.CHMP position statement on Creutzfeldt\u2010Jakob disease and plasma\u2010derived and urine\u2010derived medicinal products. [cited 2022 Dec 5]. Available from:https:\/\/www.ema.europa.eu\/en\/creutzfeldt\u2010jakob\u2010disease\u2010plasma\u2010derived\u2010urine\u2010derived\u2010medicinal\u2010products\u2010scientific\u2010guideline"},{"key":"e_1_2_14_12_1","unstructured":"European Centre for Disease Control and Prevention.The risk of variant Creutzfeldt\u2010Jakob disease transmission via blood and plasma\u2010derived medicinal products. 2021 [cited 2022 Oct 31]. Available from:https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/vCJD-blood-plasma-amended-version-July-2022-JD.pdf"},{"key":"e_1_2_14_13_1","unstructured":"vCJD transmission by blood components: risk assessment. GOV.UK. [cited 2021 Nov 4]. Available from:https:\/\/www.gov.uk\/government\/publications\/vcjd-transmission-by-blood-components-risk-assessment"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-15105-w"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02181.x"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7228.145"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12371"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12161"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-022-03280-4"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2018-315458"},{"key":"e_1_2_14_21_1","volume":"1","author":"Health Protection Agency","year":"2007","journal-title":"Health Protection Report"},{"key":"e_1_2_14_22_1","unstructured":"National CJD Research and Surveillance Unit. Surveillance. CJD. [cited 2022 Oct 31]. Available from:http:\/\/www.cjd.ed.ac.uk\/surveillance"},{"key":"e_1_2_14_23_1","unstructured":"NarayanDS BakerDP BellamyPM BentleyDA BirchallDJ Bolton\u2010MaggsDP et al.Working expert group (WEG) & writing group on behalf of the SHOT steering group. 2021. Available from:https:\/\/www.shotuk.org\/wp-content\/uploads\/myimages\/SHOT-REPORT-2021-FINAL-bookmarked-V3-November.pdf"},{"key":"e_1_2_14_24_1","first-page":"191","volume-title":"Handbook of clinical neurology","author":"Brandel J\u2010P","year":"2018"},{"key":"e_1_2_14_25_1","unstructured":"Etablissement Francais du Sang.Rapport d'Activitie 2020. Etablissement francais du sang. 2021 [cited 2022 Oct 31]. Available from:https:\/\/dondesang.efs.sante.fr\/qui-sommes-nous"},{"key":"e_1_2_14_26_1","unstructured":"The National CJD Research & Surveillance Unit. Latest Statistics. [cited 2021 Mar 15]. Available from:https:\/\/www.cjd.ed.ac.uk\/sites\/default\/files\/figs.pdf"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015626"},{"key":"e_1_2_14_28_1","unstructured":"SaBTO.Risk reduction measures for variant Creutzfeldt\u2010Jakob disease: PCWG report. GOV.UK. [cited 2021 Mar 15]. Available fromhttps:\/\/www.gov.uk\/government\/publications\/risk\u2010reduction\u2010measures\u2010for\u2010variant\u2010creutzfeldt\u2010jakob\u2010disease\u2010pcwg\u2010report"},{"key":"e_1_2_14_29_1","unstructured":"CHM 27 October 2022 \u2010 Final Summary Minutes.pdf. Powered by Box. [cited 2023 Jan 16]. Available from:https:\/\/app.box.com\/s\/jv487awvqzzsrdql0o34h9gg350ceyd4\/file\/1113226090390"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13290"},{"key":"e_1_2_14_31_1","unstructured":"Grass becomes greener for Australian blood and plasma supplies as thousands of former UK residents step up to donate. Lifeblood. [cited 2022 Oct 28]. Available from:https:\/\/www.lifeblood.com.au\/news\u2010and\u2010stories\/media\u2010centre\/media\u2010releases\/grass\u2010becomes\u2010greener\u2010australian\u2010blood\u2010and\u2010plasma\u2010supplies"},{"key":"e_1_2_14_32_1","unstructured":"Plasma Protein Therapeutics Association. Lifting of long\u2010time ban on use of UK plasma for manufacturing of immunoglobulins will help patients. Plasma Protein Therapeutics Association. [cited 2022 Oct 28]. Available from:https:\/\/www.pptaglobal.org\/media-and-information\/press-releases\/1102-lifting-of-long-time-ban-on-use-of-uk-plasma-for-manufacturing-of-immunoglobulins-will-help-patients"},{"key":"e_1_2_14_33_1","unstructured":"Plasma Protein Therapeutics Association. A missed opportunity to acknowledge EU's dependency on U.S. plasma. Plasma Protein Therapeutics Association. [cited 2022 Nov 1]. Available from:https:\/\/www.pptaglobal.org\/media-and-information\/press-releases\/1127-a-missed-opportunity-to-acknowledge-eu-s-dependency-on-u-s-plasma"},{"key":"e_1_2_14_34_1","unstructured":"Defense production act. FEMA.gov. [cited 2022 Dec 14]. Available from:https:\/\/www.fema.gov\/disaster\/defense-production-act"},{"key":"e_1_2_14_35_1","unstructured":"NHS England. Commissioning Criteria Policy for the use of therapeutic Immunoglobulin (Ig) in England. 2021 [cited 2022 Nov 28]. Available from:https:\/\/www.england.nhs.uk\/publication\/commissioning-criteria-policy-for-the-use-of-therapeutic-immunoglobulin-ig-in-england-2021\/"},{"key":"e_1_2_14_36_1","unstructured":"Joint Professional Advisory Committee. Guidelines for the blood transfusion and tissue transplantation Services of the United Kingdom. [cited 2022 Oct 28]. Available from:https:\/\/transfusionguidelines.org.uk\/"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62308-2"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12631"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3148.1999.009001003.x"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12050"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12004"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2001.41040449.x"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2003.08.004"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03590.x"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2008.01.004"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0222-9"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2007.04.008"},{"key":"e_1_2_14_48_1","unstructured":"Food and Drug Administration.Draft Quantitative Risk Assessment of vCJD Risk Potentially Associated with the Use of Human Plasma\u2010Derived Factor VIII. [cited 2022 Nov 1]. Available from:https:\/\/www.fda.gov\/media\/73877\/download"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12381"},{"key":"e_1_2_14_50_1","unstructured":"European Medicines Agency.Investigation of manufacturing processes for plasma\u2010derived medicinal products with regard to variant Creutzfeldt\u2010Jakob disease risk \u2010 scientific guideline. European Medicines Agency. 2018 [cited 2022 Nov 1]. Available from:https:\/\/www.ema.europa.eu\/en\/investigation\u2010manufacturing\u2010processes\u2010plasma\u2010derived\u2010medicinal\u2010products\u2010regard\u2010variant\u2010creutzfeldt"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.19355-0"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2015-103338"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/15265161.2016.1276643"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/15265161.2017.1293754"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12525"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13416","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.13416","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T23:07:35Z","timestamp":1729033655000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.13416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/vox.13416"],"URL":"https:\/\/doi.org\/10.1111\/vox.13416","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]}}}